This is a Phase III open-label study to assess if camizestrant improves outcomes comparedto standard endocrine therapy in patients with ER+/HER2 - early breast cancer withintermediate or high risk for disease recurrence who completed definitive locoregionaltherapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) forat least 2 years and up to 5 years. The planned duration of treatment in either arm ofthe study is 60 months.
A study of camizestrant in ER+/HER2- early breast cancer after at least 2 years of additional standard endocrine therapy.
The target population for this study consists of patients with ER+/HER2- early breast cancer who have completed definitive locoregional therapy and received at least 2 years of additional standard endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor and are currently disease-free but at intermediate or high risk of recurrence.
